BIO-PREDISC-TIA SWISS Cohort Study

This research project aims at contributing to improve TIA diagnosis and management by using PREDISC scores and specific biomarkers thought to have elevated levels in TIA patients. A swift and accurate TIA diagnosis allows starting treatment of the patient adequately and shortly after the event. The shorter the time between the event and treatment onset, the better the outcome. This approach will be an important step forward in TIA diagnosis and management, similarly to acute coronary syndrome as discussed above.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cerebrovascular Disease, Ischemic Stroke Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Ischemic Stroke Nervous System Diseases Stroke Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Ospedale Regionale di Lugano, Lugano, Canton Ticino, Switzerland

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with suspected TIA (defined as the acute onset of focal neurological symptoms lasting <24 h and presumed to be caused by brain ischemia at the time of referral) within 48 h of symptoms onset.

At least 18 years old.
Having given their Informed Consent.

Exclusion criteria

· Patients with ocular TIA (Amaurosis fugax).

Patients that still have neurological deficits at the moment of inclusion.
Contraindication to perform MRI.
For women: pregnancy.

Treatment and study plan

Primary outcomes

Levels of specific biomarkers (Platelet Basic Protein (PBP), ceruloplasmin, microRNAs, exosomal particles) in patients with suspected TIA.

Time frame: 1 year

Diagnostic performance according to PREDISC scale

Sponsors and collaborators

Lead sponsor

Dr. med. Carlo Cereda

Other Gov

Collaborators

Ente Ospedaliero Cantonale, Bellinzona

Registry information

Official study title

BIOmarkers and PREDISC Diagnostic Evaluation for Patients With Suspected Transient Ischemic Attacks: the BIOPREDISC- TIA SWISS Cohort Study

Acronym: PREDISC

Important dates

Study start: 2017
Primary completion: 2020
Study completion: 2021
First posted: Jun 21, 2019
Registry last updated: Apr 18, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed